- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04981028
The ConNeCT Study: Neurological Complications of TTP
August 2, 2021 updated by: Liverpool University Hospitals NHS Foundation Trust
The ConNeCT Study: Neurological Complications of Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura (TTP) is a rare condition, which has a very high risk of death if not recognised and given immediate treatment.
TTP is caused by a very low level of an enzyme in the body, called ADAMTS13.
A lack of ADAMTS13 causes multiple small clots to form around the body which can disrupt the blood flow to important organs.
Although survival has improved significantly, it is now being recognised that patients with TTP may suffer with longer term complications as a result of their condition; literature from the USA reports higher rates of major depression and also poor memory and reduced concentration in patients with TTP.
The investigators aim to improve the understanding of the long-term complications and review, for the first time, forward-looking data at multiple time points in patients with TTP in the UK.
Both patients with a new diagnosis and patients with a known diagnosis of TTP identified in NHS hospitals will be included, over a minimum duration of 2 years.
This will be a questionnaire based study with both doctor led and participant led questionnaires at pre-determined points in time.
By improving the understanding and comparing symptoms to that of the general population, the investigators hope to improve the support and tailor the treatments which can be offered to patients with TTP.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tina Dutt
- Phone Number: 01512826724
- Email: tina.dutt@liverpoolft.nhs.uk
Study Contact Backup
- Name: Rebecca J Shaw
- Email: R.J.Shaw@liverpool.ac.uk
Study Locations
-
-
-
Liverpool, United Kingdom
- Recruiting
- Royal Liverpool University Hospital
-
Contact:
- Rebecca J Shaw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients diagnosed with thrombotic thrombocytopenic purpura in the United Kingdom
Description
Inclusion Criteria:
1.Acute episode TTP:
- Adult male or female patient ≥18 years of age at the time of signing the consent form, with a confirmed diagnosis of TTP (initial or relapse) based on ADAMTS13 <10% 2. Known diagnosis of TTP:
- Adult male or female patient ≥ 18 years of age at time of signing the consent form, with a historical confirmed diagnosis of TTP (based on ADAMTS13 at initial presentation <10%) 3. Healthy control:
- Non-blood relative / friend / carer of patients under the care of Haematology clinics at the Royal Liverpool University hospital or other participating centres.
Exclusion Criteria:
Acute episode of TTP:
- Participants less than 18 years old at the time of signing the consent form
- Patient with ADAMTS13 greater than 10%
- Patient with cancer or transplant associated MAHA will not be included
- Patient (or NOK, where patient does not have capacity) not wishing to consent to trial
Known diagnosis of TTP:
- Participants less than 18 years old at the time of signing the consent form
- Patient with ADAMTS13 greater than 10%
- Patient with cancer or transplant associated MAHA will not be included
- Patient (or NOK, where patient does not have capacity) not wishing to consent to trial
For healthy control:
- Participants less than 18 years old at the time of signing the consent form
- Participant not wishing to consent to trial
- Any personal or family history of thrombotic microangiopathy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with acute episode of thrombotic thrombocytopenic purpura (TTP)
Any adult patients with a suspected diagnosis of TTP (defined by low platelets and anaemia with evidence of red cell breakdown) and confirmed by a low ADAMTS13 enzyme level <10%
|
For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1).
There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis.
For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2).
Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months.
The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
|
Healthy volunteers
Non-blood relative / friend / carer
|
For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1).
There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis.
For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2).
Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months.
The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
|
Patients with known diagnosis of TTP
Any adult patients with a previously confirmed diagnosis of TTP (more than 12 months ago) based on an ADAMTS13 enzyme level <10% at initial diagnosis
|
For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1).
There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis.
For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2).
Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months.
The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients with TTP with neurological complications at acute presentation
Time Frame: 1 week, 1 month, 3 months, 6 months, 12 months
|
The primary outcome is to estimate the proportion of both new acute and remission TTP patients developing neurological conditions.
These will be reported as counts and percentages with 95% confidence intervals.
If we recruit 100 patients in both groups, acute and remission, then we can estimate prevalence rates of 10% with an accuracy of +/- 6%, a 20% prevalence with an accuracy of +/-8% and a 40% prevalence with an accuracy of +/-10%.
|
1 week, 1 month, 3 months, 6 months, 12 months
|
The percentage of patients with TTP in remission with long-term neurological complications
Time Frame: 6 months, 12 months, 18 months, 2 years
|
The primary outcome is to estimate the proportion of both new acute and remission TTP patients developing neurological conditions.
These will be reported as counts and percentages with 95% confidence intervals.
If we recruit 100 patients in both groups, acute and remission, then we can estimate prevalence rates of 10% with an accuracy of +/- 6%, a 20% prevalence with an accuracy of +/-8% and a 40% prevalence with an accuracy of +/-10%.
|
6 months, 12 months, 18 months, 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of 'follow-up' patients with TTP with a depressive disorder, based on PHQ-9 scoring system, compared to the general UK population.
Time Frame: 6 month, 12 months, 18 months, 2 years
|
Secondary outcomes include proportion of TTP patients developing depressive or neurological symptoms or having reduced quality of life.
These will be reported using counts and percentages, along with 95% confidence intervals.
Also, these outcomes will be compared with the corresponding outcomes from the general population (control group).
However, as the study is not powered to detect between group differences no formal hypothesis tests will be undertaken and the data will be presented using summary statistics, counts, percentages and 95% confidence intervals.
|
6 month, 12 months, 18 months, 2 years
|
The percentage of 'follow-up' patients with TTP with neurocognitive deficit, based on TYM scoring system, compared to the general UK population.
Time Frame: 6 month, 12 months, 18 months, 2 years
|
Secondary outcomes include proportion of TTP patients developing depressive or neurological symptoms or having reduced quality of life.
These will be reported using counts and percentages, along with 95% confidence intervals.
Also, these outcomes will be compared with the corresponding outcomes from the general population (control group).
However, as the study is not powered to detect between group differences no formal hypothesis tests will be undertaken and the data will be presented using summary statistics, counts, percentages and 95% confidence intervals.
|
6 month, 12 months, 18 months, 2 years
|
The percentage of 'follow-up' patients with TTP with reduced quality of life, based on SF-36 score, compared to the general UK population.
Time Frame: 6 month, 12 months, 18 months, 2 years
|
Secondary outcomes include proportion of TTP patients developing depressive or neurological symptoms or having reduced quality of life.
These will be reported using counts and percentages, along with 95% confidence intervals.
Also, these outcomes will be compared with the corresponding outcomes from the general population (control group).
However, as the study is not powered to detect between group differences no formal hypothesis tests will be undertaken and the data will be presented using summary statistics, counts, percentages and 95% confidence intervals.
|
6 month, 12 months, 18 months, 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 25, 2020
Primary Completion (Anticipated)
June 25, 2022
Study Completion (Anticipated)
June 25, 2022
Study Registration Dates
First Submitted
July 21, 2021
First Submitted That Met QC Criteria
July 21, 2021
First Posted (Actual)
July 28, 2021
Study Record Updates
Last Update Posted (Actual)
August 9, 2021
Last Update Submitted That Met QC Criteria
August 2, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5988
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombotic Thrombocytopenic Purpura
-
Insel Gruppe AG, University Hospital BernSwiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...RecruitingThrombotic Thrombocytopenic Purpura | Congenital Thrombotic Thrombocytopenic Purpura | Familial Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Congenital | Upshaw-Schulman SyndromeUnited States, Austria, Czechia, Germany, Japan, Norway, Switzerland
-
ShireTakeda Development Center Americas, Inc.CompletedAcquired Thrombotic Thrombocytopenic Purpura (aTTP)United States, Spain, Canada, United Kingdom, France, Germany, Italy
-
Turkish Hematology AssociationSanofiRecruitingTTP - Thrombotic Thrombocytopenic PurpuraTurkey
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
Peking Union Medical College HospitalNot yet recruitingThrombotic Thrombocytopenic Purpura, AcquiredChina
-
Fundación Española de Hematología y HemoterapíaRecruitingAcquired Thrombotic Thrombocytopenic PurpuraSpain, Portugal
-
TakedaAvailableThrombotic Thrombocytopenic Purpura (TTP)
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
-
SanofiCompletedThrombotic Thrombocytopenic PurpuraJapan
-
SanofiCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
Clinical Trials on Questionnaires (including PHQ-9, TYM and SF-36)
-
Centre Hospitalier Universitaire de NīmesRecruitingCharcot Joint of Foot | OsteoarthropathyFrance
-
Mackay Memorial HospitalCompletedHyperparathyroidism | ParathyroidectomyTaiwan
-
Bahceci Health GroupUskudar UniversityUnknownWomen's Quality of Life, Sexual Life and Psychological State in Patients Undergoing Embryo TransfersDepression | Quality of Life | Anxiety State | Infertility, Female | Sexual Function and Fertility DisordersTurkey
-
Centre Hospitalier Universitaire DijonRecruiting
-
Centre Hospitalier Universitaire de BesanconActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterUniversity of Texas Southwestern Medical Center; Wake Forest UniversityActive, not recruitingBreast CancerUnited States
-
Queen Mary University of LondonCompleted
-
Case Comprehensive Cancer CenterCompletedObesity | Uterine Cancer | Stage I Endometrial AdenocarcinomaUnited States